15-Low-End Competitor May Not Stay at the Low End

When does it pay for a Low-End, Price Leader, company to skip over the Standard Leader Price Point and introduce its own Performance Leader product? It does not happen often. It did happen here under some special circumstances, especially under the benign neglect of the industry’s much larger and more powerful Standard Leaders.

Posted 4/21/08

One of your competitors may be a low-end player today. If that competitor stays at the low end, the likelihood is that its share of the market will not exceed 15%, even if it is quite successful. However, that very success may breed a significant challenge to industry leaders in the future. If the low-end competitor is earning a good return on investment, it may enter the market for the industry’s higher-end products in order to enhance its own profits and future.

The pharmaceutical industry offers a current example of the phenomenon of a low-end competitor attempting to migrate into the Standard Leader products. Indian generic drug manufacturers, including Dr. Reddy’s Laboratories Ltd., Ranbaxy Laboratories and Glenmark Pharmaceuticals have realized great success and profits in the generic drug business. These are low-end Price Leader companies. Each is a type we call a Predator competitor. Each of these companies is reinvesting some of those profits from its low-end sales into research and development on proprietary drugs. If these early stage investments into the proprietary end of the pharmaceutical business succeed, these formerly low-end companies may well challenge the Mercks and Pfizers of the world.

If this trend seems unlikely, consider that Charles Schwab, Dell, Nucor Steel and Wal-Mart all got their starts at the low end of the market. For more on low-end competitors, see “Turmoil Below: Confronting Low-End Competition” in the Tools/Perspectives section of StrategyStreet.

***

Update 2020:

Patent law in India tends to discourage the research and development of proprietary pharmaceutical preparations there. These laws aborted Indian pharmaceutical companies’ efforts to enter the market for proprietary drugs.

In 2020 the Indian pharmaceutical competitors remain Price Leaders, largely Predator producers of generic drugs. The Indian pharmaceutical industry is the world’s 3rd largest by volume and 14th largest in terms of value in 2020. India is the largest provider of generic drugs globally. The Indian pharmaceutical industry meets over 50% of global demand for various vaccines, 40% of generic demand in the U.S. and 25% of all medicine in the U.K. According to a report by IQVIA, Indian companies held a market share of around 10% in the global generics market in 2019.

Government policies in India have retarded the opportunities for Indian pharmaceutical companies to enter higher-margin segments of the industry. Creating a successful product innovation approach requires that you first stop losing customers and then respond to their clear market needs. See more HERE.

***

Update October, 2026:

As we expected, the Indian pharmaceutical manufacturers, known primarily as generic drug manufacturers in 2008, have moved up the value chain and have done so successfully. They have become even more successful drug producers with attractive returns on investment.

In the late 2010s, the leading Indian pharmaceutical manufacturers began shifting their focus from volume to value. From 2008 until 2018 or so most Indian pharmaceutical companies were traditional generic manufacturers (Price Leader companies). They specialized in efficient production of low-cost generic drugs. As the 2010s came to a close, the market witnessed a significant shift in the Indian pharmaceutical industry’s strategy to begin emphasizing high end Performance Leader products in the form of complex generics, biosimilars, novel specialty drugs and injectable therapies. The targets for these high-end products were drugs to treat specific and complex diseases with smaller patient populations and higher prices. Hence, less intense competition. This is a form of a Silver competitive strategy.

The Indian pharmaceutical manufacturers began moving up the value chain under the competitive pressure of declining margins. About three quarters of industries that become hostile do so because of the expansion of competition rather than from a decline in demand. The US generic drug industry became saturated and intensely competitive. Margins had declined since the early 2000s. The Indian manufacturers were also under pressure at home as the Indian government clamped onerous price controls on many generic drugs in order to provide low drug costs for its domestic population. These price controls made further investments in many generic drugs unattractive for the Indian domestic market.

These changes in focus and products have been wildly successful. The Indian pharmaceutical manufacturers maintain their strong US generic drug presence. In 2022 they supplied 47% of US generic prescriptions. Each of the industry’s leaders relied on the US for a mid 20s to mid 40s percentage of their exports. At the same time, the Indian pharmaceutical manufacturers’ share of the US biosimilar market has risen to 15% from nothing a few years ago. They have been able to accomplish this in part by the price umbrella set by the proprietary drug manufacturers.

The Indian pharmaceutical industry enjoys stable and attractive returns on investment with this combined Price Leader and Performance Leader product mix. Their costs remain low though not without challenges. The industry obtains about 70% of its active pharmaceutical ingredients from China. It also faces an uncertain tariff future on its sales to the US. In April 2026 the US imposed a 100% tariff on patented drugs but excluded generics and biosimilars. In July 2026 the US announced zero tariffs on generics for two years from August 2026, then 100% in August 2028 and 200% a year later.

The Indian government has been both a partner of and a problem for its domestic drug industry. The government has ramped up its investments in biotech and biosimilar initiatives. It has been inventive in creating bulk drug parks, bringing several manufacturers together in a common location to share infrastructure costs. Three parks, in Gujarat, Himachal Pradesh and Andhra Pradesh, are approved and at advanced stages, but the industry’s dependence on China has not yet fallen materially. It has also begun to align its regulation of the industry with that of the US to reduce its regulatory costs. On the negative side, the government restricted exports of 26 pharmaceutical ingredients and the medicines made from them, and banned hydroxychloroquine, during the pandemic. This, of course, damaged the Indian pharmaceutical manufacturers’ reputation as a Reliable supplier. In March 2026 a Strait of Hormuz standoff raised concern about the industry’s inputs and its shipping to the US. Reliability ranks above Convenience and Price in the Customer Buying Hierarchy, so a supply scare can cost share that a lower price cannot win back.

The move up the value chain continued into 2026. Sun Pharma’s innovative medicines reached 22% of its fiscal 2026 sales, and Indian companies filed about half of the generic drug applications submitted to the FDA in the nine months to June 2026. The Price Leader business remains under pressure, however. Price erosion hit US generic results as generic Revlimid exclusivity ended in January 2026, and Sun Pharma’s US formulation sales slipped in fiscal 2026. The market there is Hostile.

As we have seen in other industries, low-end suppliers often do not remain at the low end if there are attractive opportunities to move up the value chain. There was opportunity this time with the help of US domestic drug manufacturers, their pricing policies and the impetus of tariffs.

***

Quick Hits

Six patterns from the StrategyStreet system this story confirms.

1. A low-end competitor that earns good returns is not likely to stay at the low end. In 2008 the Indian generic drug makers were Price Leader (Pattern: A competitor or product offering below-standard performance at a very low price, selling more than half its volume below the Standard Leader’s price) companies, the type we call a Predator (Pattern: A Price Leader product or competitor with user benefits equal to, but buyer benefits below, the Standard Leader, exploiting a Leader’s Trap). By the late 2010s they were emphasizing high-end Performance Leader (Pattern: A competitor or product offering above-standard performance at a higher price, selling more than half its volume above the Standard Leader’s price) products, as Schwab, Dell, Nucor and Wal-Mart did before them. The competitor at the low end may be your next high-end rival.
2. Hostility pushes suppliers up the value chain…if the market encourages them. The US generic drug business became saturated and intensely competitive, and margins fell from the early 2000s. In a Hostile Market (Pattern: An industry with low average returns (below 7% ROE, 9% RONCE, or 7% pre-tax operating profit to assets) and sales growth under 5% per year, marked by intense price competition) the low-end stops paying. About three quarters of industries turn hostile because competition expands, not because demand falls, so the pressure rarely lifts on its own. Good returns at higher price points encourage expansion there.
3. A low-cost base can pay for the climb, and its weak link can still hurt. In 2008 the makers were reinvesting profits from low-end sales into proprietary drug research. By 2025 the industry earned stable, attractive returns on a combined low-end and high-end mix, with costs still low. Yet it draws most of its active pharmaceutical ingredients from China, a risk to its cost structure.
4. Prices held up by others invite entry underneath them. The proprietary drug makers’ pricing created a Price Umbrella (Pattern: When incumbents hold prices up, letting others discount against them and take share) that helped Indian makers move into biosimilars. In 2008 the much larger Standard Leaders (Pattern: The competitor(s) or product that sets the market’s standard performance and price, selling more than half its volume at the industry’s most common price point) paid little attention to the low-end challenger. The umbrella and the neglect did the rest.
5. Move up where the competition is thinnest. The Indian makers chose complex generics, biosimilars, specialty drugs and injectable therapies, aimed at specific, complex diseases with smaller patient populations and higher prices, Performance Leader markets. Fewer competitors can follow into those segments.
6. Customers weigh a supply failure more heavily than a price gap. The Customer Buying Hierarchy (Pattern: The consistent order customers use to evaluate alternatives: Function, Reliability, Convenience, then Price) puts Reliability (Pattern: The consistency with which a company delivers on its promises: reliability of delivery, of function, and of market presence) above Price. India’s export restrictions during the pandemic damaged the makers’ reputation as Reliable suppliers. Low prices do not repair that quickly. Supply risks amplify the problem.

***

THE SOURCES OF STRATEGYSTREET.COM: For over 30 years we observed the evolution of more than 100 industries, many hostile.  We put their facts into frameworks applicable to all industries and found patterns.  Strategystreet.com describes the inductive results of these thousands of observations and their patterns.